Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine
Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2019
|
| _version_ | 1797081150613618688 |
|---|---|
| author | Mohsen, M Vogel, M Riether, C Muller, J Salatino, S Ternette, N Gomes, A Cabral-Miranda, G El-Turabi, A Ruedl, C Kundig, T Dermime, S Knuth, A Speiser, D Bachmann, M |
| author_facet | Mohsen, M Vogel, M Riether, C Muller, J Salatino, S Ternette, N Gomes, A Cabral-Miranda, G El-Turabi, A Ruedl, C Kundig, T Dermime, S Knuth, A Speiser, D Bachmann, M |
| author_sort | Mohsen, M |
| collection | OXFORD |
| description | Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are sufficient, and whether the addition of germline antigens would enhance the therapeutic efficacy. We developed and used a personalized cancer nano-vaccine platform based on virus-like particles loaded with toll-like receptor ligands. We generated three sets of multi-target vaccines (MTV) to immunize against the aggressive B16F10 murine melanoma: one set based on germline epitopes (GL-MTV) identified by immunopeptidomics, another set based on mutated epitopes (Mutated-MTV) predicted by whole exome sequencing and a last set combines both germline and mutated epitopes (Mix-MTV). Our results demonstrate that both germline and mutated epitopes induced protection but the best therapeutic effect was achieved with the combination of both. Our platform is based on Cu-free click chemistry used for peptide-VLP coupling, thus enabling bedside production of a personalized cancer vaccine, ready for clinical translation. |
| first_indexed | 2024-03-07T01:10:28Z |
| format | Journal article |
| id | oxford-uuid:8cd36f66-19b1-4e4d-ab0f-3fe9cabd93d9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:10:28Z |
| publishDate | 2019 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:8cd36f66-19b1-4e4d-ab0f-3fe9cabd93d92022-03-26T22:47:08ZTargeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8cd36f66-19b1-4e4d-ab0f-3fe9cabd93d9EnglishSymplectic Elements at OxfordFrontiers Media2019Mohsen, MVogel, MRiether, CMuller, JSalatino, STernette, NGomes, ACabral-Miranda, GEl-Turabi, ARuedl, CKundig, TDermime, SKnuth, ASpeiser, DBachmann, MPersonalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are sufficient, and whether the addition of germline antigens would enhance the therapeutic efficacy. We developed and used a personalized cancer nano-vaccine platform based on virus-like particles loaded with toll-like receptor ligands. We generated three sets of multi-target vaccines (MTV) to immunize against the aggressive B16F10 murine melanoma: one set based on germline epitopes (GL-MTV) identified by immunopeptidomics, another set based on mutated epitopes (Mutated-MTV) predicted by whole exome sequencing and a last set combines both germline and mutated epitopes (Mix-MTV). Our results demonstrate that both germline and mutated epitopes induced protection but the best therapeutic effect was achieved with the combination of both. Our platform is based on Cu-free click chemistry used for peptide-VLP coupling, thus enabling bedside production of a personalized cancer vaccine, ready for clinical translation. |
| spellingShingle | Mohsen, M Vogel, M Riether, C Muller, J Salatino, S Ternette, N Gomes, A Cabral-Miranda, G El-Turabi, A Ruedl, C Kundig, T Dermime, S Knuth, A Speiser, D Bachmann, M Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
| title | Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
| title_full | Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
| title_fullStr | Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
| title_full_unstemmed | Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
| title_short | Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
| title_sort | targeting mutated plus germline epitopes confers pre clinical efficacy of an instantly formulated cancer nano vaccine |
| work_keys_str_mv | AT mohsenm targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT vogelm targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT rietherc targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT mullerj targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT salatinos targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT ternetten targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT gomesa targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT cabralmirandag targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT elturabia targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT ruedlc targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT kundigt targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT dermimes targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT knutha targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT speiserd targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine AT bachmannm targetingmutatedplusgermlineepitopesconferspreclinicalefficacyofaninstantlyformulatedcancernanovaccine |